Emergent Biosolutions Stock Total Debt

EBS Stock

USD 1.89 0.03 1.56%

Emergent Biosolutions fundamentals help investors to digest information that contributes to Emergent Biosolutions' financial success or failures. It also enables traders to predict the movement of Emergent Stock. The fundamental analysis module provides a way to measure Emergent Biosolutions' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Emergent Biosolutions stock.

Short Long Term Debt Total Total Assets

Total Debt To Capitalization is likely to drop to 0.54 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Emergent Biosolutions Company Total Debt Analysis

Emergent Biosolutions' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Total Debt

Bonds

+

Notes

More About Total Debt | All Equity Analysis

Current Emergent Biosolutions Total Debt

1.41 B

Most of Emergent Biosolutions' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Emergent Biosolutions is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Emergent Total Debt Driver Correlations

Understanding the fundamental principles of building solid financial models for Emergent Biosolutions is extremely important. It helps to project a fair market value of Emergent Stock properly, considering its historical fundamentals such as Total Debt. Since Emergent Biosolutions' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Emergent Biosolutions' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Emergent Biosolutions' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Good Will	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Current Deferred Revenue	Long Term Debt	Short Term Investments	Property Plant Equipment	Deferred Long Term Liab	Treasury Stock	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.97	0.88	0.75	0.53	0.44	0.62	0.99	0.77	0.72	0.79	0.64	0.53	0.69	0.93	0.98	0.9	-0.87	0.9	0.78	0.91	0.2	0.68	0.85	-0.19	-0.6
Total Stockholder Equity	0.97		0.75	0.7	0.46	0.42	0.52	0.92	0.69	0.62	0.66	0.56	0.6	0.69	0.87	0.97	0.87	-0.82	0.92	0.76	0.91	0.09	0.66	0.83	-0.05	-0.52
Net Debt	0.88	0.75		0.64	0.5	0.48	0.7	0.93	0.7	0.76	0.89	0.7	0.28	0.59	0.91	0.83	0.81	-0.8	0.71	0.69	0.79	0.3	0.45	0.74	-0.44	-0.62
Retained Earnings	0.75	0.7	0.64		0.81	0.53	0.72	0.76	0.98	0.62	0.8	0.74	0.58	0.45	0.75	0.73	0.7	-0.78	0.77	0.55	0.71	0.22	0.75	0.73	-0.04	-0.51
Accounts Payable	0.53	0.46	0.5	0.81		0.79	0.92	0.56	0.81	0.24	0.79	0.93	0.69	0.62	0.67	0.42	0.53	-0.45	0.71	0.63	0.65	0.1	0.6	0.64	0.23	-0.05
Net Receivables	0.44	0.42	0.48	0.53	0.79		0.88	0.45	0.54	-0.06	0.72	0.85	0.69	0.77	0.64	0.34	0.48	-0.23	0.63	0.76	0.6	-0.32	0.15	0.57	0.4	0.08
Good Will	0.62	0.52	0.7	0.72	0.92	0.88		0.67	0.76	0.28	0.92	0.98	0.62	0.73	0.79	0.49	0.63	-0.46	0.72	0.76	0.72	0.03	0.42	0.69	0.1	-0.13
Total Liab	0.99	0.92	0.93	0.76	0.56	0.45	0.67		0.8	0.77	0.84	0.68	0.47	0.67	0.94	0.95	0.89	-0.87	0.85	0.77	0.88	0.26	0.66	0.84	-0.27	-0.63
Total Current Assets	0.77	0.69	0.7	0.98	0.81	0.54	0.76	0.8		0.67	0.84	0.76	0.51	0.45	0.76	0.73	0.69	-0.78	0.75	0.56	0.71	0.25	0.73	0.71	-0.14	-0.56
Short Term Debt	0.72	0.62	0.76	0.62	0.24	-0.06	0.28	0.77	0.67		0.57	0.34	-0.07	0.05	0.59	0.76	0.56	-0.88	0.5	0.19	0.57	0.62	0.63	0.47	-0.76	-0.79
Intangible Assets	0.79	0.66	0.89	0.8	0.79	0.72	0.92	0.84	0.84	0.57		0.89	0.49	0.65	0.91	0.69	0.77	-0.67	0.73	0.74	0.77	0.15	0.45	0.76	-0.16	-0.47
Common Stock	0.64	0.56	0.7	0.74	0.93	0.85	0.98	0.68	0.76	0.34	0.89		0.6	0.7	0.8	0.54	0.65	-0.55	0.79	0.72	0.78	0.12	0.51	0.7	0.06	-0.11
Current Deferred Revenue	0.53	0.6	0.28	0.58	0.69	0.69	0.62	0.47	0.51	-0.07	0.49	0.6		0.78	0.6	0.46	0.55	-0.27	0.71	0.77	0.59	-0.3	0.45	0.68	0.64	0.05
Long Term Debt	0.69	0.69	0.59	0.45	0.62	0.77	0.73	0.67	0.45	0.05	0.65	0.7	0.78		0.77	0.59	0.74	-0.35	0.76	0.98	0.72	-0.21	0.34	0.77	0.41	0.02
Short Term Investments	0.93	0.87	0.91	0.75	0.67	0.64	0.79	0.94	0.76	0.59	0.91	0.8	0.6	0.77		0.86	0.87	-0.77	0.88	0.85	0.89	0.11	0.56	0.88	-0.09	-0.49
Property Plant Equipment	0.98	0.97	0.83	0.73	0.42	0.34	0.49	0.95	0.73	0.76	0.69	0.54	0.46	0.59	0.86		0.87	-0.91	0.87	0.68	0.89	0.22	0.69	0.8	-0.24	-0.63
Deferred Long Term Liab	0.9	0.87	0.81	0.7	0.53	0.48	0.63	0.89	0.69	0.56	0.77	0.65	0.55	0.74	0.87	0.87		-0.77	0.82	0.81	0.84	0.11	0.53	0.8	-0.06	-0.46
Treasury Stock	-0.87	-0.82	-0.8	-0.78	-0.45	-0.23	-0.46	-0.87	-0.78	-0.88	-0.67	-0.55	-0.27	-0.35	-0.77	-0.91	-0.77		-0.78	-0.45	-0.8	-0.53	-0.75	-0.74	0.45	0.61
Net Tangible Assets	0.9	0.92	0.71	0.77	0.71	0.63	0.72	0.85	0.75	0.5	0.73	0.79	0.71	0.76	0.88	0.87	0.82	-0.78		0.78	0.97	0.11	0.73	0.84	0.08	-0.28
Long Term Debt Total	0.78	0.76	0.69	0.55	0.63	0.76	0.76	0.77	0.56	0.19	0.74	0.72	0.77	0.98	0.85	0.68	0.81	-0.45	0.78		0.76	-0.19	0.38	0.81	0.31	-0.17
Capital Surpluse	0.91	0.91	0.79	0.71	0.65	0.6	0.72	0.88	0.71	0.57	0.77	0.78	0.59	0.72	0.89	0.89	0.84	-0.8	0.97	0.76		0.15	0.65	0.81	-0.08	-0.33
Short Long Term Debt	0.2	0.09	0.3	0.22	0.1	-0.32	0.03	0.26	0.25	0.62	0.15	0.12	-0.3	-0.21	0.11	0.22	0.11	-0.53	0.11	-0.19	0.15		0.49	0.26	-0.67	-0.11
Cash And Equivalents	0.68	0.66	0.45	0.75	0.6	0.15	0.42	0.66	0.73	0.63	0.45	0.51	0.45	0.34	0.56	0.69	0.53	-0.75	0.73	0.38	0.65	0.49		0.61	-0.1	-0.31
Net Invested Capital	0.85	0.83	0.74	0.73	0.64	0.57	0.69	0.84	0.71	0.47	0.76	0.7	0.68	0.77	0.88	0.8	0.8	-0.74	0.84	0.81	0.81	0.26	0.61		0.05	-0.25
Net Working Capital	-0.19	-0.05	-0.44	-0.04	0.23	0.4	0.1	-0.27	-0.14	-0.76	-0.16	0.06	0.64	0.41	-0.09	-0.24	-0.06	0.45	0.08	0.31	-0.08	-0.67	-0.1	0.05		0.54
Capital Stock	-0.6	-0.52	-0.62	-0.51	-0.05	0.08	-0.13	-0.63	-0.56	-0.79	-0.47	-0.11	0.05	0.02	-0.49	-0.63	-0.46	0.61	-0.28	-0.17	-0.33	-0.11	-0.31	-0.25	0.54

Click cells to compare fundamentals

Emergent Total Debt Historical Pattern

Today, most investors in Emergent Biosolutions Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Emergent Biosolutions' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Emergent Biosolutions total debt as a starting point in their analysis.

Emergent Biosolutions Total Debt

Timeline

In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Competition

Predict Emergent Biosolutions

Short Long Term Debt Total Over Time

Emergent Short Long Term Debt Total

Short Long Term Debt Total

1.7 Billion

At this time, Emergent Biosolutions' Short and Long Term Debt Total is comparatively stable compared to the past year.

Based on the latest financial disclosure, Emergent Biosolutions has a Total Debt of 1.41 B. This is 48.9% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The total debt for all United States stocks is 73.56% higher than that of the company.

Emergent Total Debt Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Emergent Biosolutions' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Emergent Biosolutions could also be used in its relative valuation, which is a method of valuing Emergent Biosolutions by comparing valuation metrics of similar companies.

Emergent Biosolutions is currently under evaluation in total debt category among related companies.

Emergent Biosolutions Institutional Holders

Institutional Holdings refers to the ownership stake in Emergent Biosolutions that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Emergent Biosolutions' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Emergent Biosolutions' value.

		Shares
State Street Corporation	2023-12-31	1.1 M
Two Sigma Investments Llc	2023-12-31	1 M
D. E. Shaw & Co Lp	2023-09-30	936.5 K
Prescott Group Capital Management Llc	2023-12-31	853.3 K
Assenagon Asset Management Sa	2023-12-31	834.4 K
Dimensional Fund Advisors, Inc.	2023-12-31	658.2 K
Qube Research & Technologies	2023-12-31	621.2 K
Bridgeway Capital Management, Llc	2023-12-31	616.5 K
Renaissance Technologies Corp	2023-12-31	547.3 K
Blackrock Inc	2023-12-31	9.4 M
Vanguard Group Inc	2023-12-31	3 M

Emergent Fundamentals

	Return On Equity	-0.75
	Return On Asset	-0.048
	Profit Margin	(0.72) %
	Operating Margin	(0.18) %
	Current Valuation	866.03 M
	Shares Outstanding	52.39 M
	Shares Owned By Insiders	1.88 %
	Shares Owned By Institutions	78.65 %
	Number Of Shares Shorted	5.89 M
	Price To Earning	1.67 X
	Price To Book	0.17 X
	Price To Sales	0.10 X
	Revenue	1.12 B
	Gross Profit	290.1 M
	EBITDA	(34.4 M)
	Net Income	(223.8 M)
	Cash And Equivalents	642.6 M
	Cash Per Share	7.28 X
	Total Debt	1.41 B
	Debt To Equity	0.56 %
	Current Ratio	3.92 X
	Book Value Per Share	12.44 X
	Cash Flow From Operations	(34.1 M)
	Short Ratio	4.76 X
	Earnings Per Share	(14.85) X
	Price To Earnings To Growth	1.55 X
	Target Price	5.0
	Number Of Employees	1.6 K
	Beta	1.19
	Market Capitalization	100.59 M
	Total Asset	3.17 B
	Retained Earnings	734 M
	Working Capital	28.2 M
	Current Asset	537.41 M
	Current Liabilities	99.61 M
	Net Asset	3.17 B

About Emergent Biosolutions Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Emergent Biosolutions's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Emergent Biosolutions using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Emergent Biosolutions based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with Emergent Biosolutions

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Emergent Biosolutions position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Emergent Biosolutions will appreciate offsetting losses from the drop in the long position's value.

The ability to find closely correlated positions to Emergent Biosolutions could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Emergent Biosolutions when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Emergent Biosolutions - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Emergent Biosolutions to buy it.

The correlation of Emergent Biosolutions is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Emergent Biosolutions moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Emergent Biosolutions moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Emergent Biosolutions can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Emergent Biosolutions is a strong investment it is important to analyze Emergent Biosolutions' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Emergent Biosolutions' future performance. For an informed investment choice regarding Emergent Stock, refer to the following important reports:

How To Invest In Emergent

Details

Is Emergent Stock a good investment?

Details

What is Emergent Biosolutions' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Emergent Biosolutions Piotroski F Score and Emergent Biosolutions Altman Z Score analysis.

For more information on how to buy Emergent Stock please use our How to Invest in Emergent Biosolutions guide.

Note that the Emergent Biosolutions information on this page should be used as a complementary analysis to other Emergent Biosolutions' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for Emergent Stock analysis

When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.

	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges

Is Emergent Biosolutions' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Emergent Biosolutions. If investors know Emergent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Emergent Biosolutions listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.022

Earnings Share

(14.85)

Revenue Per Share

20.494

Quarterly Revenue Growth

(0.16)

Return On Assets

(0.05)

The market value of Emergent Biosolutions is measured differently than its book value, which is the value of Emergent that is recorded on the company's balance sheet. Investors also form their own opinion of Emergent Biosolutions' value that differs from its market value or its book value, called intrinsic value, which is Emergent Biosolutions' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Emergent Biosolutions' market value can be influenced by many factors that don't directly affect Emergent Biosolutions' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Emergent Biosolutions' value and its price as these two are different measures arrived at by different means. Investors typically determine if Emergent Biosolutions is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Emergent Biosolutions' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Emergent Biosolutions Stock Total Debt

Emergent Biosolutions Company Total Debt Analysis

Total Debt

Bonds

+

Notes

Current Emergent Biosolutions Total Debt

Emergent Total Debt Driver Correlations

Emergent Total Debt Historical Pattern

Emergent Short Long Term Debt Total

Short Long Term Debt Total

1.7 Billion

Emergent Total Debt Peer Comparison

Emergent Biosolutions Institutional Holders

Emergent Fundamentals

About Emergent Biosolutions Fundamental Analysis

Pair Trading with Emergent Biosolutions

Complementary Tools for Emergent Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY